BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.

Abteilung für Nephrologie und Rheumatologie Göttingen Germany

Arthritis and Rheumatism Associates Wheaton MD USA

Biosimilars Development Amgen Inc Thousand Oaks CA USA

Institute of Rheumatology Prague 2 Czech Republic

Instituto de Investigación Hospital 12 de Octubre Madrid Spain

Internal Medicine Rheumatology Division Metroplex Clinical Research Center 8144 Walnut Hill Lane Suite 800 Dallas TX 75231 USA

Zobrazit více v PubMed

Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum. 1990;20(3):190–200. doi: 10.1016/0049-0172(90)90060-S. PubMed DOI

Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016. 10.1136/annrheumdis-2016-209166. PubMed PMC

Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3. PubMed PMC

Ventola CL. Biosimilars: part 2: potential concerns and challenges for p&t committees. P T. 2013;38(6):329–335. PubMed PMC

Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016. 10.1007/s11926-016-0601-0. PubMed

Gulácsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, Péntek M. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015. 10.1586/1744666X.2015.1090313. PubMed

European Medicines Agency . Guideline on similar biological medicinal products. 2013.

European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/WC500020062.pdf. Accessed Aug 31.

US Food and Drug Administration . Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. 2015.

US Food and Drug Administration . Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015.

US Food and Drug Administration . Scientific considerations in demonstrating biosimilarity to a reference product. 2015.

US Food and Drug Administration . Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2016.

The Pharmaceuticals and Medical Devices Agency . Guideline for the quality, safety, and efficacy assurance of follow-on biologics. 2009.

European Medicines Agency . Guideline on similar biological medicinal products. 2014.

Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017. 10.1007/s40259-017-0218-5. PubMed PMC

Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015. 10.1016/j.semarthrit.2015.04.002. PubMed

Olech E. Biosimilars: rationale and current regulatory landscape. Semin Arthritis Rheum. 2016. 10.1016/j.semarthrit.2016.01.001. PubMed

Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Semin Arthritis Rheum. 2016. 10.1016/j.semarthrit.2016.01.002. PubMed

European Medicines Agency. European public assessment reports. 2018. https://www.ema.europa.eu/en/medicines/download-medicine-data. Accessed 17 Aug 2018.

US Food and Drug Administration . FDA-approved biosimilar products. 2018.

Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):321–338. doi: 10.1007/s40259-016-0184-3. PubMed DOI PMC

Velayudhan J, Chen YF, Rohrbach A, Pastula C, Maher G, Thomas H, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):339–351. doi: 10.1007/s40259-016-0185-2. PubMed DOI PMC

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017. 10.1016/j.jaad.2016.12.014. PubMed

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017. 10.1111/bjd.15857. PubMed

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017. 10.1136/annrheumdis-2016-210459. PubMed PMC

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. PubMed DOI

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011. 10.1093/rheumatology/ker124. PubMed

Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782–3789. doi: 10.1002/art.22214. PubMed DOI

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014. 10.1093/rheumatology/ket260. PubMed PMC

Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010. 10.1186/ar3147. PubMed PMC

European Medicines Agency. Summary of product characteristics. Humira (adalimumab). 2018. https://www.ema.europa.eu/documents/product-information/humira-epar-product-information_en.pdf.

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02114931